| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Department of Internal Medicine II, Friedrich-Schiller-Universität Jena, D-07740 Jena, Germany [M. R., K. H.]; Oncoscreen GmbH, D-07745 Jena, Germany [W. S., P. H., D. B.]; and Academic Medical Center, Laboratory of Genetic Metabolic Diseases, 1100 DE Amsterdam, the Netherlands [A. B. P. V. K., A. H. V. G.]
Deficiency of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in 5-fluorouracil (5-FU) catabolism, has been linked to toxic side effects of 5-FU. The most prominent mutation of the DPD gene resulting in severe DPD deficiency is a G to A mutation in the GT 5'-splice recognition site of intron 14 (exon 14-skipping mutation). The corresponding mRNA lacks exon 14, and the enzymatic activity of the translated DPD protein is virtually absent. We developed a reverse transcription-PCR-based assay suitable for routine identification of the exon 14-skipping mutation and screened a control cohort of 851 Caucasian individuals as well as a cohort of 25 cancer patients reported by their physicians to have suffered from WHO grades 3–4 toxicity upon 5-FU chemotherapy. Within the control cohort, in total, eight heterozygotes were detected (0.94%): one heterozygote in 51 healthy donors, (1.96%); five heterozygotes in 572 hospital patients (0.87%); and two heterozygotes in 228 colorectal tumor patients (0.88%). Among the 25 patients with severe 5-FU-related toxicity, 5 (20%) were heterozygous and 1 (4%) was homozygous for the exon 14-skipping mutation. All six patients had experienced WHO grade 4 myelosuppression. Lethal outcome was seen in the homozygous and two of the heterozygous cases. We conclude that carriers of the DPD exon 14-skipping mutation are at significantly increased risk to experience life-threatening myelosuppression upon 5-FU treatment, even when the allelic status is heterozygous. These data lead us to suggest routine testing for the exon 14-skipping mutation before 5-FU treatment.
This article has been cited by other articles:
|
|
 |
|
  M. Schwab, U. M. Zanger, C. Marx, E. Schaeffeler, K. Klein, J. Dippon, R. Kerb, J. Blievernicht, J. Fischer, U. Hofmann, et al. Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group J. Clin. Oncol., May 1, 2008; 26(13): 2131 - 2138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oie, M. Ono, H. Fukushima, F. Hosoi, H. Yano, Y. Maruyama, M. Kojiro, T. Terada, K. Hirano, M. Kuwano, et al. Alteration of dihydropyrimidine dehydrogenase expression by IFN-{alpha} affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells Mol. Cancer Ther., August 1, 2007; 6(8): 2310 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H.M. Schellens Capecitabine Oncologist, February 1, 2007; 12(2): 152 - 155. [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Ichikawa, T. Takahashi, K. Suto, Y. Sasaki, and R. Hirayama Orotate Phosphoribosyltransferase Gene Polymorphism Predicts Toxicity in Patients Treated with Bolus 5-Fluorouracil Regimen. Clin. Cancer Res., July 1, 2006; 12(13): 3928 - 3934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Seck, S. Riemer, R. Kates, T. Ullrich, V. Lutz, N. Harbeck, M. Schmitt, M. Kiechle, R. Diasio, and E. Gross Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals Clin. Cancer Res., August 15, 2005; 11(16): 5886 - 5892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Steiner, M Seule, B Steiner, I Bauer, M Freund, C H Kohne, and P Schuff-Werner 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case J. Clin. Pathol., May 1, 2005; 58(5): 553 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. P. van Kuilenburg, R. Meinsma, B. A. Zonnenberg, L. Zoetekouw, F. Baas, K. Matsuda, N. Tamaki, and A. H. van Gennip Dihydropyrimidinase Deficiency and Severe 5-Fluorouracil Toxicity Clin. Cancer Res., October 1, 2003; 9(12): 4363 - 4367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ezzeldin, M. R. Johnson, Y. Okamoto, and R. Diasio Denaturing High Performance Liquid Chromatography Analysis of the DPYD Gene in Patients with Lethal 5-Fluorouracil Toxicity Clin. Cancer Res., August 1, 2003; 9(8): 3021 - 3028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lazar, S. Jan Weissenborn, D. Grundemann, R. Berkels, U. Fuhr, H. Pfister, and E. Schomig Detection of a Novel 1905C->T Mutation within the Dihydropyrimidine Dehydrogenase Gene and Potential for Misclassification with the Exon 14-skipping Mutation Clin. Chem., April 1, 2003; 49(4): 707 - 708. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Weinshilboum Inheritance and Drug Response N. Engl. J. Med., February 6, 2003; 348(6): 529 - 537. [Full Text] [PDF]
|
|
|
|
|
|
F. Innocenti and M. J. Ratain Correspondence re: Raida, M. et al., Prevalence of a Common Point Mutation in the Dihydropyrimidine Dehydrogenase (DPD) Gene within the 5'-Splice Donor Site of Intron 14 in Patients with Severe 5-Fluorouracil (5-FU)-related Toxicity Compared with Controls. Clin. Cancer Res., 7: 2832-2839, 2001. Clin. Cancer Res., May 1, 2002; 8(5): 1314 - 1316. [Full Text] [PDF]
|
|
|
|
|
|
D. Behnke, M. Raida, K.-O. Kliche, and U. Pichlmeier Reply Clin. Cancer Res., May 1, 2002; 8(5): 1315 - 1316. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
